Ovarian cancer is the deadliest of all gynecological diseases because its diagnosis and treatment still pose many problems. Surgical excision, hormone therapy, radiation, chemotherapy, or targeted therapy for eradicating the main tumor and halting the spread of metastases are among the treatment options available to individuals with ovarian cancer, depending on the disease’s stage. Tumor DNA that circulates in a patient’s bodily fluids has been studied recently as a possible novel biomarker for a number of cancers, as well as a means of quantifying tumor size and evaluating the efficacy of cancer therapy. The most significant alterations that we could find in the ctDNA of ovarian cancer patients—such as chromosomal instability, somatic mutations, and methylation—are discussed in this review. Additionally, we talk about the utility of ctDNA in diagnosis, prognosis, and therapy response prediction for these patients.
卵巢癌是所有妇科疾病中致死率最高的，其诊断与治疗至今仍面临诸多挑战。根据疾病分期，卵巢癌患者可选择的治疗方案包括手术切除、激素治疗、放射治疗、化疗或靶向治疗，以消除主要肿瘤并抑制转移灶扩散。近期研究表明，患者体液中循环的肿瘤DNA可能成为多种癌症的新型生物标志物，同时可作为量化肿瘤大小和评估癌症治疗效果的监测手段。本综述重点探讨在卵巢癌患者循环肿瘤DNA中观察到的最显著改变，包括染色体不稳定性、体细胞突变和甲基化现象。此外，我们还讨论了循环肿瘤DNA在这些患者的诊断、预后评估及治疗反应预测中的临床应用价值。
肿瘤(癌症)患者之家